Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.132
Abstract: Background: ModraDoc006 is a novel, oral tablet formulation of docetaxel To enhance bioavailability, it is co-administered with ritonavir (r), an inhibitor of cytochrome P450 3A4 and Pglycoprotein The oral combination, denoted ModraDoc006/r, has potential advantages… read more here.
Keywords: phase iib; modradoc006; docetaxel; option ... See more keywords